Επιστημονικές μελέτες Femarelle® – DT56a

3,1K

Η ασφάλεια και αποτελεσματικότητα του DT56a και των προϊόντων της σειράς Femarelle® φαίνεται από τις ακόλουθες μελέτες και την υποστήριξη των προϊόντων από κορυφαίους ιατρούς παγκόσμιου κύρους.

1. Yoles I. et al. Efficacy and Safety of Standard Versus Low Dose of Femarelle® (Tofupill) for the Treatment of
   Menopausal Symptoms. J. of Clin Exper Obstet Gynecol 2004; 31(2):123-26.
2. Labos G., Trakakis E. et al. Efficacy and Safety of DT56a (Femarelle®) compared to hormone therapy in
   Greek postmenopausal women. J Endocrinol. Invest. 2013; 36(7):521-6.
3. Genazzani A.R., et al. Brain region responsiveness to DT56a (Femarelle®) Administration on
   Allopregnanolone and Opioid Content in Ovariectomized Rats. Menopause 2009; 16(5):1037-43.
4. Genazzani A., Nachtigall L., Panay N. & Yoles I. Symposium: 2 Continents, 3 Cultures, 4 Countries, 2,000
   Women and Femarelle®; 13th World Congress on Menopause. Rome, Italy, June 2011.
5. Sánchez-Borrego R., Mendoza N., Llaneza P. A Prospective Study of DT56a (Femarelle®) for the Treatment
   of Menopause Symptoms; Climacteric. 2015 ;18(6):813-6.
6. Nachtigall M. et al. A Prospective Study of DT56a (Femarelle®) for the Treatment of Postmenopausal
   Vaginal Atrophy. Menopause book of abstract of the NAMS 22nd Annual Meeting, Sept, 201, p. 55.
7. Yoles I. et al. Tofupill/Femarelle® (DT56a) – a New Phyto-Selective Estrogen Receptor Modulator-like
   Substance for the Treatment of Postmenopausal Bone Loss. Menopause 2003; 10(6):522-25.
8. Somjen D., Katzburg S., Lieberherr M., Hendel D., Yoles I., DT56a Stimulates Gender-Specific Human
   Cultured Bone Cells In Vitro. J. of Steroid Biochemistry & Molecular Biology 2006; 98(1):90-96.
9. Yoles I., Lilling G. Pharmacological Doses of the Natural phyto-SERM DT56a (Femarelle®) Have no Effect on
   MCF-7 Breast Cancer Cell-Line. European J. of Obstetrics & Gynecology & Reproductive Biology 2006;
   130(1):140-141.
10. Nachtigall M., et al. The Selective Estrogen Receptor Modulator DT56a (Femarelle®) does not affect
    Platelet Reactivity in Normal or Thrombophilic Postmenopausal Women. Menopause 2011; 18,(3):285-
    288.
11. Nachtigall L. et al. Association of Oral but not Transdermal Estrogen Therapy with Enhanced Platelet
    Reactivity in a Subset of Postmenopausal Women. Menopause 2009; 16(2):407-412.
12. Somjen D., Yoles I. DT56a (Tofupill/Femarelle®) Selectively Stimulates Creatine Kinase Specific Activity
    in Skeletal Tissues of Rats but not in the Uterus. J. of Steroid Biochemistry & Molecular Biology 2003;
    86(1):93-98.
13. Somjen D. et al. DT56a (Femarelle®/Tofupill) Stimulates Bone Formation in Female Rats. British J. of
    Obstetrics & Gynecology 2005; 112(7): 981-985.
14. Somjen D. et al. The Effects of Native and Synthetic Estrogenic Compounds as well as Vitamin D Less-
    Calcemic Analogs on Adipocytes Content in Rat Bone Marrow. J. Endocrinol Invest. 2011; 34(2):106-10.
15. Oropeza M.V., Orozco S., Ponce H., Campos M.G. Tofupill Lacks Peripheral Estrogen-Like Actions in the Rat
    Reproductive Tract. Reproductive Toxicology 2005; 20(2):261-66.
16. Somjen D., Yoles I. DT56a (Femarelle®): a Natural Selective Estrogen Receptor Modulator (SERM). J. of
    Steroid Biochemistry & Molecular Biology 2007; 104:252-58.
17. Somjen D. et al. DT56a (Femarelle®); Contrary to Estradiol-17 β is Effective in Human Derived Female
    Osteoblast in Hyperglycemic Condition. J. Steroid Biochem Mol Biol. 2011; 123:25-29.
18. Bedell S., Nachtigall M., Naftolin F. The Pros and Cons of Plant Estrogens for Menopause; J. Steroid
    Biochem. Mol. Biol. 2014; 139:225-236.
19. Sánchez-Borrego R., et al. Efficacy and Safety of a Phyto-SERM as an Alternative to Hormone Therapy.
    Climacteric. 2015 June; 18(3):350-7.
20. Somjen D. et al. Interaction Between the Effects of the Selective Estrogen Modulator Femarelle® and a
    Vitamin D Analog in Human Umbilical Artery Vascular Smooth Muscle Cells. J Steroid Biochem Mol Biol.
    2017; 174:9-13.

Αγοράστε το Femarelle® που ταιριάζει στις δικές σας ανάγκες:

Femarelle® Rejuvenate: Για γυναίκες 40+ ετών, για τις πρώτες ορμονικές διαταραχές και βαρύ/έντονο προεμμηνορυσιακό σύνδρομο.

Femarelle® Recharge: Για γυναίκες 50+ ετών ή που διανύουν την μετάβαση στην εμμηνόπαυση και βιώνουν έντονα συμπτώματα όπως εξάψεις, νυχτερινές εφιδρώσεις, διαταραχές στον ύπνο, αλλαγές στη διάθεση, διαταραχές στη λίμπιντο κά.

Femarelle® Unstoppable: Για γυναίκες στη μετεμμηνόπαυση και όταν υπάρχει επιπλέον ανάγκη υποστήριξης του μυοσκελετικού συστήματος, του ουρογεννητικού συστήματος και της φυσιολογικής πνευματικής λειτουργίας.